NCT05690503View on ClinicalTrials.gov

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Post-acute Sequelae of COVID-19Depressive SymptomsCognitive Dysfunction
Interventions
DRUG

CI-581a

Medication infusion intravenously over 90 minutes.

DRUG

CI-581b

Medication infusion intravenously over 90 minutes.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER